Lymphoma

Maternal, Fetal Considerations for the Treatment and Management of Lymphoma During Pregnancy

Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.

Tazemetostat Yields Promising Results in Patients With Follicular Lymphoma

By

Lauren Dembeck, PhD

Tazemetostat yielded clinically meaningful, durable responses and was well tolerated in patients with relapsed or refractory follicular lymphoma.

Promising, Early Results for Combined HDAC and mTOR Inhibition in Relapsed/Refractory Hodgkin Lymphoma

By

Susan Moench, PhD, PA-C

Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.

Modern Radiation Therapy Limits Radiation Doses to Organs at Risk in Hodgkin Lymphoma

By

Lauren Dembeck, PhD

Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.

Keytruda Approval Expands Classical Hodgkin Lymphoma Indication

By

Brian Park, PharmD

The expanded approval was based on data from the randomized, open-label, phase 3 KEYNOTE-204 trial.

Brentuximab Vedotin Plus Nivolumab as Chemotherapy-Free Strategy for Hodgkin Lymphoma in Older Patients

By

Lauren Dembeck, PhD

Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.

Case Report Details COVID-19 Reinfection in Immunocompromised Patient

By

Leah Lawrence

A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.

Pregnant Patients With Non-Hodgkin Lymphoma May Receive Chemotherapy

By

Patricia Chaney

Pregnant patients with non-Hodgkin lymphoma may be able to receive CHOP-like chemotherapy during pregnancy with some risks.

Obinutuzumab With Cytarabine Induction for Transplant-Eligible Mantle Cell Lymphoma

By

Vicki Moore, PhD

In a phase 2 trial, obinutuzumab added to induction therapy showed promising activity and tolerability for transplant-eligible mantle cell lymphoma.

Classical Hodgkin Lymphoma: Patients Face Unnecessary Risk of Death Unrelated to Lymphoma

By

Jonathan Goodman, MPhil

Investigators characterized the risks of stage- and cause-specific mortality among patients with classical Hodgkin lymphoma treated with chemotherapy.

Ibrutinib Effectiveness in Symptomatic, Previously Treated Waldenström Macroglobulinemia

By

Jonathan Goodman, MPhil

Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.

New Analysis of the Tumor Microenvironment Reveals 3 Subtypes in Large B-Cell Lymphoma of the Brain

By

Monique Brouillette

The signaling pathways detected may shed light on new treatment strategies.

Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphomas

By

Vicki Moore, PhD

Investigators assessed safety and efficacy outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.

Recall of Specific Types of Breast Implants and Tissue Expanders Has Far-Reaching Impact on Patients With Breast Cancer

By

Susan Moench, PhD, PA-C

In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.

Follicular Lymphoma: Interactions With Surrounding Cells to Identify Therapeutic Targets

By

Jonathan Goodman, MPhil

Characterizing gene expression profiles of FL cells from intrafollicular and extrafollicular regions may help to identify future therapeutic targets.

Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations

By

Lauren Dembeck, PhD

Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.

Radiotherapy Response Time Did Not Dictate Outcomes for Gastrointestinal Low-Grade B-Cell Lymphoma

By

Leah Lawrence

Delayed evaluation could decrease unnecessary invasive tests.

Managing Skin Flare Reactions in Patients Receiving Mogamulizumab for Cutaneous T-cell Lymphoma

By

Susan Moench, PhD, PA-C

Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.

Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow Up

By

Lauren Dembeck, PhD

Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.

2021 Update on Diagnosis, Risk Stratification, and Management of Cutaneous B-Cell Lymphomas

By

Rita Aghjayan

Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.

Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans

By

Jessica Wapner

Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.

Low-Dose Anti-PD1 Therapies in Relapsed/Refractory Classical Hodgkin Lymphoma

By

Vicki Moore, PhD

A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.

Characterization of Neurotoxicity After CAR-T in LBCL

By

Andrea S. Blevins Primeau, PhD, MBA

Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.

Lipid Microenvironment With B-Cell Lymphoma and Natural Killer Cell Function

By

Vicki Moore, PhD

Lipid changes in the B-cell lymphoma microenvironment may influence natural killer cell metabolism and function.

Trends Suggest More AYA Lymphoma Survivors Being Engaged in Survivorship Discussions, But Improvements Needed

By

Susan Moench, PhD, PA-C

In this study, researchers determined that the quantity and quality of discussions regarding survivorship and late effects of treatment between AYA lymphoma survivors and their oncologists is improving, but survivorship information is still lacking.

Expert Q&A: Understanding the Oncogenic Role of HIV in Burkitt Lymphoma

By

Tori Rodriguez, MA, LPC

While the rate of certain HIV-linked non-Hodgkin lymphomas has declined since the introduction of ART, the incidence of Burkitt lymphoma has remained steady.

Survival Outcomes and HIV Status Among Patients With Plasmablastic Lymphoma

By

Jonathan Goodman, MPhil

Researchers studied clinical characteristics linked to overall survival and lymphoma-specific survival in patients with plasmablastic lymphoma.

Improving Survival in Younger Patients With Waldenström Macroglobulinemia

By

Jonathan Goodman, MPhil

Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.

G-CSF Appears Safe in CAR-T–Treated Patients With Refractory/Relapsed B-Cell Lymphoma

By

Agata Boxe

The treatment reduced hospital stay but not neutropenia duration or infection rate.

Biomarker Identified for Anti–PD-1 Treatment in Natural Killer/T-Cell Lymphoma

By

Leah Lawrence

All responders were found to have the same structural rearrangements.

Strategies for Managing AEs, Patient Adherence in Acalabrutinib for Mantle Cell Lymphoma

By

Susan Moench, PhD, PA-C

Researchers at UT MD Anderson Cancer Center in Houston present tools that support patient adherence to acalabrutinb in the setting of MCL.

Immunohistochemistry as a Surrogate for TP53 Sequencing in Mantle Cell Lymphoma

By

Vicki Moore, PhD

Identifying TP53 missense mutations through routine analysis is needed for patients with mantle cell lymphoma.

Risk-Stratified Treatments May Offer Cures in Relapsed Pediatric Anaplastic Large Cell Lymphoma

By

Lauren Dembeck, PhD

Study results suggest allogeneic SCT as standard consolidation therapy in pediatric patients with progression during frontline therapy or relapse of a CD3-positive ALCL.

No Benefit From Early Rituximab Intensification During DLBCL Treatment

By

Lauren Dembeck, PhD

Researchers in the Netherlands conducted HOVON-84 to determine what benefit, if any, early rituximab intensification had in adult patients with untreated DLBCL.

Event-Free Survival at 24 Months as a Surrogate Endpoint for T Cell Lymphoblastic Lymphoma

By

Jonathan Goodman, MPhil

Among patients with T cell lymphoblastic leukemia, event-free survival at 24 months is a strong surrogate endpoint for long-term survival.

Long-Term Zanubrutinib Treatment Effective for Majority of Patients With Waldenström Macroglobulinemia

By

Jonathan Goodman, MPhil

The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.

Monjuvi Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

By

Brian Park, PharmD

Tafasitamab-cxix is a humanized Fc-modified monoclonal antibody that targets CD19 antigen on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including DLBCL.

Two Trials Evaluate CAR-T Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma

By

Vicki Moore, PhD

CD30 CAR-T cell treatment after lymphodepletion may produce antitumor activity without significant toxicity in relapsed or refractory Hodgkin lymphoma.

High Molecular Response With Lenalidomide, Rituximab in Untreated Follicular Lymphoma

By

Patricia Chaney

Researchers for the RELEVANCE study measured MRD in a subset of patients to compare the molecular response of patients receiving R2 vs R-chemo.

First CAR T-Cell Therapy Approved for Mantle Cell Lymphoma

By

Brian Park, PharmD

The FDA has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel; Kite Pharma) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

PET-Based Treatment Approach for Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

A prospective NCTN PET-directed analysis aimed to eradicate the short- and long-term toxicities associated with RT in patients with limited-stage DLBCL.

Allogeneic-HSCT Outcomes With Varied Donor Sources in Adult T-Cell Leukemia/Lymphoma

By

Vicki Moore, PhD

Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.

Real-World Data Confirm Early Efficacy of Axi-Cel in Refractory DLBCL

By

Andrea S. Blevins Primeau, PhD, MBA

A retrospective study found similar efficacy and toxicity outcomes among patients with refractory DLBCL who were treated with axi-cel outside of trial inclusion criteria.

Systematic Analysis Reveals Genomic Mutational Frequencies in MCL

By

Jonathan Goodman, MPhil

The authors noted that these findings should be seen as a reference for the mutational landscape in MCL at baseline and at disease progression after treatment.

Examining Progress and Future Directions in Follicular Lymphoma Treatment

By

Patricia Chaney

Researchers examine how far follicular lymphoma treatment has come, what limitations still remain, and where the management of the disease is headed.

Diagnosing and Managing Patients With Primary Pancreatic Lymphoma

By

Roxanne Nelson, RN, BSN

Because primary pancreatic lymphoma is a rare disease, optimal diagnostic and therapeutic protocols have not yet been established.

Selinexor in Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

A clinical trial suggests efficacy and a manageable adverse event profile with selinexor for the treatment of relapsed or refractory DLBCL.

Considerations for the Diagnostic Work-Up of Breast Implant–Associated Lymphoma

By

Andrea S. Blevins Primeau, PhD, MBA

Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.

T-Cell Lymphoblastic Lymphoma: Promising Results From Children’s Oncology Group AALL0434 Study

By

Jonathan Goodman, MPhil

AALL0434, one of the largest prospective studies of T-LL, resulted in successful disease-free and overall survival outcomes.

Addition of Rituximab to Chemotherapy for Pediatric High-Risk, Mature B-Cell NHL

By

Lauren Dembeck, PhD

For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.

Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

By

Brian Park, PharmD

The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.